Muñoz N, Wahrendorf J, Bang L J, Crespi M, Thurnham D I, Day N E, Ji Z H, Grassi A, Yan L W, Lin L G
Lancet. 1985 Jul 20;2(8447):111-4. doi: 10.1016/s0140-6736(85)90223-5.
A randomised double-blind intervention trial was carried out in Huixian, Henan Province, People's Republic of China, to determine whether combined treatment with retinol, riboflavine, and zinc could lower the prevalence of precancerous lesions of the oesophagus. 610 subjects in the age group 35-64 were randomised to receive once a week the active treatment (15 mg [50 000 IU] retinol, 200 mg riboflavine, and 50 mg zinc) or placebo. Both at entry to the study and at the end of the treatment, 13.5 months later, the subjects were examined, with an emphasis on signs of vitamin A and riboflavine deficiences, and riboflavine, retinol, beta-carotene, and zinc levels were measured. Compliance was excellent. The final examination, on 567 (93%) subjects, included oesophagoscopy and at least two biopsies. The intervention did not affect the prevalence of oesophageal lesions: after one year, the prevalence of oesophagitis with or without atrophy or dysplasia was 45.3% in the placebo group and 48.9% in the vitamin/zinc treated group.
在中国河南省辉县开展了一项随机双盲干预试验，以确定视黄醇、核黄素和锌联合治疗是否能降低食管癌前病变的患病率。将610名年龄在35 - 64岁之间的受试者随机分组，使其每周接受一次活性治疗（15毫克[50000国际单位]视黄醇、200毫克核黄素和50毫克锌）或安慰剂。在研究开始时以及13.5个月后的治疗结束时，对受试者进行检查，重点关注维生素A和核黄素缺乏的体征，并测量核黄素、视黄醇、β - 胡萝卜素和锌的水平。依从性良好。对567名（93%）受试者进行的最终检查包括食管镜检查和至少两次活检。该干预措施并未影响食管病变的患病率：一年后，安慰剂组有或无萎缩或发育异常的食管炎患病率为45.3%，维生素/锌治疗组为48.9%。
